<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03455166</url>
  </required_header>
  <id_info>
    <org_study_id>BIO-ARP</org_study_id>
    <nct_id>NCT03455166</nct_id>
  </id_info>
  <brief_title>Identification of New Prognostic Markers in Psoriatic Arthritis</brief_title>
  <official_title>Identification of New Prognostic Markers in Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Galeazzi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Galeazzi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identification of possible markers associated with the onset and / or progression of&#xD;
      psoriatic arthritis through comparison in patients with psoriasis alone (Ps) and patients&#xD;
      with psoriasis with joint involvement (PsA), plasma levels of a panel of cytokines referable&#xD;
      to the Th17 pathway , together with serum levels of MMPs, TIMPs and markers of bone&#xD;
      remodeling.&#xD;
&#xD;
      The primary objective of this study is to verify whether the arthropathy component has an&#xD;
      effect on the metabolic activity of osteoblasts. This will be determined through the study of&#xD;
      the differences in serum concentrations, between Ps and PsA subjects, of &quot;CTx&quot;, the parameter&#xD;
      best characterized in terms of analytical variability and intra- and inter-individual&#xD;
      variability, in the field of bone metabolism.&#xD;
&#xD;
      The secondary objective is the verification of the differences in serum concentrations of the&#xD;
      series of parameters specified above, in order to define a complete pattern of variations&#xD;
      that can identify the molecular pathways involved in the definition of psoriatic arthropathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Different markers concentration</measure>
    <time_frame>1 year</time_frame>
    <description>Measurement in serum of: MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-12, MMP-13, TIMP-1, TIMP-2, TIMP-3, TIMP-4, OPG, RANKL, PINP, CTx-I, DKK1, SOST,IL-1beta, IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, INFg, sCD40L, TNFalfa. Correlation with Ps or PsA, and with the severity of the disease</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Psoriasis</condition>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Psoriasis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Psoriatic arthropathy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serum Markers</intervention_name>
    <description>Serum Markers</description>
    <arm_group_label>Psoriasis</arm_group_label>
    <arm_group_label>Psoriatic arthropathy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥18 years&#xD;
&#xD;
          -  For Ps group:&#xD;
&#xD;
        plaque psoriasis no previous treatment with biological drugs&#xD;
&#xD;
        - For PsA group: plaque psoriasis with arthropathy no previous treatment with biological&#xD;
        drugs but in treatment as per clinical practice or, alternatively, last treatment with drug&#xD;
        suspended by a number of days double compared to the half-life of the drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Neoplasia in progress or previous (&lt;5 years)&#xD;
&#xD;
          -  Other acute or chronic inflammatory diseases&#xD;
&#xD;
          -  Other rheumatological diseases&#xD;
&#xD;
          -  Metabolic diseases of the primitive bone&#xD;
&#xD;
          -  Recent bone fractures (&lt;6 months)&#xD;
&#xD;
          -  Anxiety, psychosis, depressive disorders&#xD;
&#xD;
          -  Inability to understand the information provided by the recruiter doctor&#xD;
&#xD;
          -  For Ps group:&#xD;
&#xD;
        treatment with biological drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2018</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

